Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.59 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.59 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.59 |
| ▸ | CD69 | Q07108 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.45 |
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.45 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616129 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL13479975 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL29401541 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL31682911 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL7720011 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL6820124 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL5518959 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL3229913 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL10488345 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 | |
| SCHEMBL29456417 | 1.00 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270339-A1 | TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND USES THEREFOR | ALECTOR LLC | 2025-08-28 | — | — | US | claimed |
| US-12398192-B2 | Cancer treatment with 237 CAR-T cell based therapeutics recognizing the Tn epitope | THE UNIVERSITY OF CHICAGO (US) | 2025-08-26 | — | — | US | claimed |
| EP-4562044-A2 | TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND USES THEREFOR | Alector LLC (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119677526-A | Improved glycan-dependent immunotherapeutic bispecific fusion proteins and chimeric antigen receptors | 加利福尼亚大学董事会 | 2025-03-21 | — | — | CN | claimed |
| CN-119497721-A | Transferrin receptor antigen binding domains and uses thereof | 艾莱克特有限责任公司 | 2025-02-21 | — | — | CN | claimed |
| EP-4086628-B1 | METHOD, DEVICE, AND KIT FOR POPULATION SCREENING FOR CANCER, CANCER RECURRENCE AND PRECANCEROUS CONDITIONS IN SYMPTOM FREE INDIVIDUALS | SHAMSUDDIN ABULKALAM MOHAMMED (US) | 2024-07-03 | — | — | EP | claimed |
| US-20240166765-A1 | INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES | EXELIXIS, INC. | 2024-05-23 | — | — | US | claimed |
| WO-2024026472-A2 | TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND USES THEREFOR | ALECTOR LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230310637-A1 | Glycan-dependent Immunotherapeutic Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023137399-A2 | INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES | ICONIC THERAPEUTICS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-11666660-B2 | Glycan-dependent immunotherapeutic molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | claimed |
| US-20230159657-A1 | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods | EXELIXIS, INC. | 2023-05-25 | — | — | US | claimed |
| EP-4178608-A1 | INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES | Iconic Therapeutics, Inc. (US) | 2023-05-17 | — | — | EP | claimed |
| CN-115960262-A | Canine parvovirus-like particle for displaying CDV epitope as well as construction method and application thereof | 四川农业大学 | 2023-04-14 | — | — | CN | claimed |
| EP-4086628-A1 | METHOD, DEVICE, AND KIT FOR POPULATION SCREENING FOR CANCER, CANCER RECURRENCE AND PRECANCEROUS CONDITIONS IN SYMPTOM FREE INDIVIDUALS | Shamsuddin, Abulkalam, Mohammed (US) | 2022-11-09 | — | — | EP | claimed |
| CN-110275014-B | Method for rapidly identifying metastasis of papillary thyroid carcinoma cervical lymph nodes in operation | 江苏省原子医学研究所 | 2022-07-01 | — | — | CN | claimed |
| US-20220153871-A1 | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods | EXELIXIS, INC. | 2022-05-19 | — | — | US | claimed |
| US-20220047631-A1 | CANCER TREATMENT WITH 237 CAR-T CELL BASED THERAPEUTICS RECOGNIZING THE TN EPITOPE | THE UNIVERSITY OF CHICAGO (US) | 2022-02-17 | — | — | US | claimed |
| JP-11127866-A | — | — | None | — | — | JP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166765-A1 | INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES | F3, TNF, TFPI | MAPK1 3963/4885LGALS3 722/4885LGALS8 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.